Press2021-08-31T13:16:16-04:00

Press

October 2020

Is It Too Late for Novavax to Profit From a Covid-19 Vaccine?

“Novavax uses a tried-and-true method to produce immunity,” said Asher Rogovy, who is the Chief Investment Officer at Magnifina. “The news media and social media are almost certain to hype up reports of side effects during the first round of vaccination. Vaccine hesitancy is growing, and in 2018 almost half of US citizens refused a flu vaccine. Waiting a few more months for Novavax’s vaccine candidate would appeal to vaccine hesitant individuals who are not fully anti-vax.” 

Read full article 

[…]

Go to Top